ELF3 and Fabry disease: In the case of patients with Fabry disease with specific (“amenable”) mutations, treatment with chaperones may represent the appropriate approach while for the remaining Fabry patients, the combined therapy such as ERT with substrate reduction therapy, might have a benefic effect.